Gossamer Bio Inc

NASDAQ:GOSSUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Its product candidate Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. In contrast to the three classes of marketed vasodilatory therapies for PAH, its seralutinib has the potential to reverse pathological remodeling by addressing mechanisms that underlie PAH. Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways. In addition to PAH, seralutinib holds the potential as a therapeutic option for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Contact Information

Headquarters

3013 Science Park RdSAN DIEGO, CA, United States 92121-1101

Phone

858-922-0718

Fax

302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer, Co-Founder

Faheem Hasnain

Chief Operating Officer, Chief Financial Officer

Bryan Giraudo

Executive Vice President - Regulatory

Caryn Peterson

Executive Vice President - Technical Operations and Administration

Christian Waage

Chief Medical Officer

Richard Aranda